---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-016179"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2026-04-10T23:59:59+00:00"
generated_at: "2026-05-15T06:45:02.534373+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech amends ATM agreement to remove $3M cap on share sales

## Summary
- Amendment No. 1 to Equity Distribution Agreement with Maxim Group removes the prior $3,000,000 limit on shares sold.
- Company's common stock continues to be offered at-the-market under existing shelf registration statement (Form S-3).
- A prospectus supplement was filed to increase the number of shares available for sale in the offering.
- Maxim Group remains the exclusive sales agent for the at-the-market offering.

## SEC filing metadata
- accession: 0001493152-26-016179
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2026-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/0001493152-26-016179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-016179
- JSON: https://secwatch.observer/filing/0001493152-26-016179.json
- Plain text: https://secwatch.observer/filing/0001493152-26-016179.txt

## Source-grounded claims
- claim_id: c37b58aab0cffdfe9c1ba27f7a684443f5f34ab7
  claim: AIM ImmunoTech Inc. amended Amendment No. 1 with Maxim Group LLC (effective 2026-04-10).
  evidence_excerpt: On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/946644/000149315226016179/0001493152-26-016179-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.